Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism

NCT01149291 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01149291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01149291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Observational
Overall status
Completed
Start date
July 31, 2011
Completion date
December 31, 2014
Enrollment
511 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease, secondary hyperparathyroidism